PA
ACRS icon

Parallel Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Parallel Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34K Buy
+357
New +$1.21K ﹤0.01% 3476
2023
Q3 		– Sell
-500
Closed -$5.18K – 3361
2023
Q2 		$5.18K Hold
500
– – ﹤0.01% 2416
2023
Q1 		$4.04K Sell
500
-100
-17% -$1.27K ﹤0.01% 2483
2022
Q4 		$9.45K Hold
600
– – ﹤0.01% 2050
2022
Q3 		$9K Sell
600
-24
-4% -$378 ﹤0.01% 2018
2022
Q2 		$9K Buy
624
+24
+4% +$336 ﹤0.01% 2006
2022
Q1 		$11K Buy
+600
New +$8.19K ﹤0.01% 1948
2021
Q3 		– Sell
-100
Closed -$2K – 3045
2021
Q2 		$2K Sell
100
-1,100
-92% -$25K ﹤0.01% 2517
2021
Q1 		$30K Sell
1,200
-400
-25% -$7.82K ﹤0.01% 1408
2020
Q4 		$10K Sell
1,600
-2,250
-58% -$9.49K ﹤0.01% 1769
2020
Q3 		$10K Hold
3,850
– – ﹤0.01% 1721
2020
Q2 		$6K Hold
3,850
– – ﹤0.01% 1881
2020
Q1 		$4K Hold
3,850
– – ﹤0.01% 1937
2019
Q4 		$7K Sell
3,850
-400
-9% -$663 ﹤0.01% 1838
2019
Q3 		$5K Hold
4,250
– – ﹤0.01% 1890
2019
Q2 		$9K Buy
4,250
+1,250
+42% +$6.81K ﹤0.01% 1622
2019
Q1 		$18K Sell
3,000
-1,250
-29% -$8.29K ﹤0.01% 1255
2018
Q4 		$31K Buy
4,250
+1,340
+46% +$13.8K ﹤0.01% 912
2018
Q3 		$42K Buy
+2,910
New +$49.9K 0.01% 875

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Parallel Advisors's ACRS Position: Q1 2026 in Review

Parallel Advisors opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 357 shares worth $1.34K. The stake represents ﹤0.01% of the portfolio and ranks #3476 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in ACRS as recently as Q2 2023.

Parallel Advisors first reported a position in ACRS in Q3 2018 and has held it in 19 quarters since. The position peaked at $42K in Q3 2018. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Parallel Advisors held 357 shares of Aclaris Therapeutics worth $1.34K as of Q1 2026.
  • Aclaris Therapeutics was a new Parallel Advisors position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3476 holding.
  • Parallel Advisors first reported a position in Aclaris Therapeutics in Q3 2018 and has held it in 19 quarters since.
  • Parallel Advisors's Aclaris Therapeutics position peaked at $42K in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.